Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
RIVFLOZA injection contains nedosiran, a double-stranded small interfering RNA (siRNA) with four covalently attached N-acetyl-D-galactosamine (GalNAc) residues. Nedosiran targets lactate dehydrogenase A (LDHA) in hepatocytes via GalNAc-mediated delivery.
The structural formula of the nedosiran sodium drug substance is presented below:
 |
The molecular formula of nedosiran sodium is C662H808F19N231O413P57S6Na57 with a molecular weight of 22,238 Da. Nedosiran sodium is freely soluble in water.
RIVFLOZA Pre-filled Syringe is supplied as a clear, sterile, preservative-free, colorless-to-yellow solution for subcutaneous injection containing either the equivalent of 160 mg (present as 170 mg nedosiran sodium salt) nedosiran in 1 mL or the equivalent of 128 mg (present as 136 mg nedosiran sodium salt) nedosiran in 0.8 mL of water for injection and sodium hydroxide and/or hydrochloric acid to adjust the pH to ~ 7.2.
RIVFLOZA vial is supplied as a clear, sterile, preservative-free, colorless-to-yellow solution for subcutaneous injection containing the equivalent of 80 mg (present as 85 mg nedosiran sodium salt) nedosiran in 0.5 mL of water for injection and sodium hydroxide and/or hydrochloric acid to adjust the pH to ~ 7.2.
RIVFLOZA is indicated to lower urinary oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥ 30 mL/min/1.73 m² [see CLINICAL PHARMACOLOGY], Clinical Studies].
RIVFLOZA is administered subcutaneously once monthly at the recommended doses shown in Table 1.
Dosing is based on actual body weight.
Table 1: RIVFLOZA Dose Regimen in Adults and Pediatric Patients (2 years of age and older)
| Body weight | |||
| Less than 39 kg | 39 kg to less than 50 kg | 50 kg and above | |
| Age 2 to less than 12 years | 3.3 mg/kg | 128 mg | 160 mg |
| Age 12 years and older | 128 mg | 160 mg | |
If a planned dose is missed, administer RIVFLOZA as soon as possible. If the planned dose is missed by more than 7 days, administer RIVFLOZA as soon as possible and resume monthly dosing from the most recently administered dose.
Pre-filled syringe: A healthcare provider, caregiver, or patient 12 years of age and older may inject RIVFLOZA using the pre-filled syringe. In pediatric patients 2 to less than 12 years of age who weigh ≥ 39 kg, a healthcare provider or caregiver may inject RIVFLOZA using the prefilled syringe.
Vials: RIVFLOZA vials are intended for use under the guidance and supervision of a healthcare provider. Adult patients or caregivers may administer RIVFLOZA after proper training in preparing RIVFLOZA vials for administration, if a healthcare provider determines that it is appropriate, and with medical follow-up as necessary.
Administer RIVFLOZA by subcutaneous injection to the abdomen (at least 2 inches from the navel) or the upper thigh. Do not inject into a vein or into scarred or bruised skin.
Inspect visually for particulate matter and discoloration prior to injection. RIVFLOZA should be colorless-to-yellow and particle free. If the solution is cloudy or contains particulate matter, do not use.
Instructions for delivering the dosage are provided in the Instructions for Use leaflets enclosed with the RIVFLOZA Pre-filled Syringe and single-dose vial.
Discard the unused portion of the drug.
RIVFLOZA Injection 160 mg/mL (present as 170 mg nedosiran sodium) is a clear, colorless-to-yellow solution available as follows:
RIVFLOZA is a clear, sterile, preservative-free, colorless-to-yellow solution available in singledose pre-filled syringes and single-dose vials in cartons containing one unit each.
Table 3: RIVFLOZA Presentations
| RIVFLOZA Presentation | Total Volume | Total amount available in presentation | Concentration | NDC number |
| Single-dose vial | 0.5 mL | 80 mg | 160 mg / mL | NDC 0169-5308-01 |
| Single-dose Pre-filled Syringe | 0.8 mL | 128 mg | 160 mg / mL | NDC 0169-5307-08 |
| Single-dose Pre-filled Syringe | 1 mL | 160 mg | 160 mg / mL | NDC 0169-5306-10 |
Store refrigerated at 2°C to 8°C (36°F to 46°F). RIVFLOZA can be stored, if needed, at 15°C to 30°C (59°F to 86°F) for a maximum of 28 days (4 weeks). Do not freeze. Store in original carton, away from direct heat and light.
Table 4: Storage Conditions for RIVFLOZA
| Refrigerated 2°C to 8°C (36°F to 46°F) | Room Temperature at 15°C to 30°C (59°F to 86°F) | |
| RIVFLOZA | Until expiration date | Maximum 28 days (4 weeks) |
For more information contact: Dicerna Pharmaceuticals, Inc. A Novo Nordisk company, Novo Nordisk Inc. 800 Scudders Mill Road, Plainsboro, NJ 08536, 1-844-906-5099. Manufactured by: Pyramid Laboratories, 3598 Cadillac Ave, Costa Mesa, CA 92626. Revised: Mar 2025
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of RIVFLOZA has been evaluated in one placebo-controlled clinical trial (PHYOX2) and one open-label extension study (PHYOX3). Across these studies, 29 adults and 12 children with PH1 have been treated with RIVFLOZA. Patients with PH1 in these studies ranged in age from 9 to 46 years at first dose. The median duration of exposure was approximately 15 months (range 1-29 months). Overall, 38 patients with PH1 were treated for at least 6 months, 24 patients for at least 12 months, and 16 patients for at least 18 months.
In the randomized, placebo-controlled, double-blind PHYOX2 trial in pediatric and adult patients 9 to 46 years of age, 18 patients with PH1 received RIVFLOZA and 11 patients received placebo. Of the 18 patients treated with RIVFLOZA, 17 patients received ≥ 5 months of active treatment. The most common adverse reactions were injection site reactions, which were reported in 7 patients with PH1 (39%) on RIVFLOZA as compared to no patients on placebo.
Injection site reactions included erythema, pain, bruising, and rash and were generally mild and did not lead to discontinuation of treatment.
In the single-arm extension study (PHYOX3) that included 40 patients with PH1, additional injection site reactions included atrophy in 1 patient (3%).
The safety of RIVFLOZA has additionally been evaluated in one single-arm clinical study (PHYOX8) in 15 pediatric patients 2 to less than 12 years of age with PH1 and an eGFR >30 mL/min/1.73 m². Injection site reactions were reported in 2 patients (13%). Overall, the RIVFLOZA safety profile was similar to that seen in PHYOX2.
No Information provided
Included as part of the PRECAUTIONS section.
Advise the patient to read the FDA-approved patient labeling (PATIENT INFORMATION and Instructions for Use).
Instruct patients/caregivers on the appropriate dose of RIVFLOZA to use, the timing of the dose, how and where to inject subcutaneously, and what to do if a dose is missed.
Long-term studies to assess carcinogenic risk of nedosiran have not been conducted.
Nedosiran was not genotoxic in the in vitro bacterial mutagenicity, in vitro micronucleus assays (human peripheral blood lymphocytes) and in vivo bone marrow micronucleus assay in mice.
Weekly subcutaneous administration of nedosiran at doses of 500, 1000, or 2000 mg/kg or of a mouse-specific (pharmacologically active) analog at a dose of 10 mg/kg to male mice for 4 weeks prior to and throughout mating, and to female mice for 2 weeks prior to and throughout mating and to gestation day 7 did not affect male or female fertility or early embryonic development.
Available data from reports of pregnancy in clinical trials with RIVFLOZA are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.
In animal reproduction studies, no adverse developmental effects were observed when nedosiran was administered to pregnant mice at doses up to approximately 58 times the maximum recommended human dose (MRHD) of 160 mg nedosiran (equivalent to 170 mg nedosiran sodium) per dose, based on body surface area (BSA) or upon administration of a mouse-specific (pharmacologically active) analog. Subcutaneous administration of nedosiran to pregnant rabbits during the period of organogenesis at doses approximating the MRHD resulted in increased fetal loss in the presence of maternal toxicity. Adverse developmental outcomes (fetal cardiovascular and skeletal malformations) were observed at a dose approximately 2 times the MRHD (see Data). Nedosiran is not pharmacologically active in rabbits or mice. The cause for the embryo-fetal toxicities observed in rabbits remains unclear.
The estimated background risk of major birth defects and miscarriage in the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Animal Data
In mice, subcutaneous administration of nedosiran at doses up to 2000 mg/kg/dose (approximately 58 times the MRHD based on BSA) or a mouse-specific (pharmacologically active) analog (10 mg/kg/dose) during organogenesis (dosing on gestation days 6, 8, 10, 12, and 14 for nedosiran; gestation days 3 and 10 for the analog) did not have adverse effects on embryofetal development.
Subcutaneous administration of nedosiran (0, 2, 6 or 20 mg/kg/dose) to pregnant rabbits during organogenesis (dosing on gestation days 7, 9, 11, 13, 15, 17, and 19) resulted in maternal toxicity on the basis of body weight loss of up to 6.5% following the first dose in the 6 and 20 mg/kg/dose groups. Higher post-implantation loss and lower numbers of live fetuses occurred at ≥ 6 mg/kg/dose (exposures equivalent to the MRHD based on BSA), and fetal cardiovascular and skeletal malformations occurred at the 20 mg/kg/dose (2 times the MRHD based on BSA). At the 2 mg/kg/dose, which is below the MRHD, no adverse findings were seen.
In a pre- and postnatal study in mice, subcutaneous administration of nedosiran (0, 250, 500, or 1000 mg/kg/dose) or a mouse-specific (pharmacologically active) analog (10 mg/kg/dose) from implantation (dosing on gestational days 6, 8, 10, 12, 14, 16) to weaning (dosing on lactation days 1, 8, 15, 20) did not have adverse effects on the growth, viability, development and reproductive performance of the offspring.
There are no data on the presence of RIVFLOZA in human or animal milk, the effects on the breastfed child, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for RIVFLOZA and any potential adverse effects on the breastfed infant from RIVFLOZA or from the underlying maternal condition.
The safety and effectiveness of RIVFLOZA have been established in pediatric patients aged 2 years and older. Use of RIVFLOZA in these age groups is supported by evidence from an adequate and well-controlled trial in adult and pediatric patients 9 years of age and older (PHYOX2), and a single-arm study in pediatric patients 2 to less than 12 years of age (PHYOX8) [see Clinical Studies].
The safety and effectiveness of RIVFLOZA in patients younger than 2 years of age have not been established.
Clinical studies of RIVFLOZA did not include patients aged 65 and over to determine whether they respond differently from younger patients. No dose adjustment is recommended in patients ≥ 65 years old [see CLINICAL PHARMACOLOGY].
No dose adjustment of RIVFLOZA is recommended for patients with mild hepatic impairment (total bilirubin ≤ upper limit of normal [ULN] and aspartate aminotransferase [AST] > ULN or total bilirubin > 1 to 1.5 times ULN and any AST).
RIVFLOZA has not been studied in patients with moderate or severe hepatic impairment (total bilirubin > 1.5 ULN with any AST) [see CLINICAL PHARMACOLOGY].
No dose adjustment is recommended in patients with an estimated glomerular filtration rate (eGFR) of ≥ 30 mL/min/1.73 m² [see CLINICAL PHARMACOLOGY ].
RIVFLOZA has not been studied in PH1 patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²).
No Information provided
None.
Nedosiran is a double-stranded siRNA, conjugated to GalNAc aminosugar residues. After subcutaneous administration, the GalNAc-conjugated sugars bind to asialoglycoprotein receptors (ASGPR) to deliver nedosiran to hepatocytes.
Nedosiran reduces levels of hepatic lactate dehydrogenase (LDH) via the degradation of LDHA messenger ribonucleic acid (mRNA) in hepatocytes through RNA interference. The reduction of hepatic LDH by nedosiran reduces the production of oxalate by the liver, thereby reducing subsequent oxalate burden.
The pharmacodynamic effects of RIVFLOZA were evaluated after single-dose and monthly-dose administration in patients with PH1. Dose-dependent reductions in urinary oxalate were observed in the single-dose range of 1.5 mg/kg to 6.0 mg/kg. With the recommended monthly dose regimen of RIVFLOZA, onset of effect was observed at the first measurement (30 days after the first dose) and the effect persisted with continued monthly dosing [see Clinical Studies].
At the recommended dose, RIVFLOZA does not lead to clinically relevant QT interval prolongation.
The pharmacokinetic (PK) properties of RIVFLOZA were evaluated following administration of single and multiple dosages in patients with PH1 or PH2 as summarized in Table 2.
Table 2: Pharmacokinetic Parameters of Nedosiran
| Nedosiran | ||
| General Information | ||
| Steady State Exposure | Cmax [Mean (%CV)] | 844 (44) ng/mL |
| AUC0-last [Mean (%CV)] | 13600 (36) ng*h/mL | |
| Dose Proportionality | Nedosiran exhibited a dose-proportional increase in plasma exposure following single subcutaneous doses from 1.5 to 6.0 mg/kg. Nedosiran exhibited time-independent pharmacokinetics with multiple doses of 160 mg once monthly (body weight ≥ 50 kg), 128 mg once monthly (body weight < 50 kg), or 3.3 mg/kg once monthly in the age range of 6 to 11 years. |
|
| Accumulation | No accumulation of nedosiran was observed in plasma following repeated monthly dosing. | |
| Absorption | ||
| Tmax [Median (Range)] | 6 (2 to 12) hours | |
| Distributiona | ||
| Estimated Vz/F | 126 L | |
| Protein Binding | 85.6% | |
| Elimination | ||
| Half-Life (Mean (%CV)]) | 15 (68) hours | |
| Estimated CL/F | 5.7 L/hr | |
| Metabolism | ||
| Primary Pathway | Nedosiran is metabolized by endo- and exonucleases to shorter oligonucleotides. | |
| Excretion | ||
| Primary Pathway | Approximately 27% of the administered nedosiran dose is excreted unchanged into the urine within 24 hours of dosing. | |
| a Nedosiran distributes primarily to the liver after subcutaneous administration. Cmax = maximum plasma concentration; AUC0-last = area under the plasma concentration-time curve from time of administration (0) to the last measurable time point (last); Tmax = time to maximum concentration; Vz/F = apparent volume of distribution; CV = coefficient of variation; CL/F = apparent clearance. |
||
No clinically significant differences in the pharmacokinetics or pharmacodynamics of nedosiran were observed based on age (2 to 73 years old), sex, race/ethnicity, mild-to-moderate renal impairment (eGFR 30 to 89 mL/min/1.73 m²]) [see Use In Specific Populations] or mild hepatic impairment as assessed using the National Cancer Institute Organ Dysfunction Working Group criteria (total bilirubin ≤ ULN and AST > ULN; or total bilirubin > 1 to 1.5 x ULN and any AST) [see Use In Specific Populations].
At the recommended clinical dose, PK exposure of nedosiran is similar in adult and pediatric patients 2 years of age and older.
Concomitant use of pyridoxine (vitamin B6) did not have a significant impact on the PK of nedosiran.
In vitro studies demonstrated that nedosiran was not an inhibitor or inducer of cytochrome P450 (CYP) enzymes and was neither a substrate nor an inhibitor of efflux and uptake transporters.
As with all oligonucleotides, including RIVFLOZA, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.
Across all clinical studies in the nedosiran development program, including patients with PH1 dosed with RIVFLOZA, RIVFLOZA did not induce or boost anti-drug antibodies (ADA). Among 79 patients tested with the ADA assay, none developed treatment-emergent ADA.
PHYOX2 was a randomized, double-blind trial comparing RIVFLOZA and placebo in patients aged 6 years or older with PH1 or PH2 and an eGFR ≥ 30 mL/min/1.73 m² (NCT03847909). Too few PH2 patients were enrolled to evaluate efficacy in the PH2 population. Therefore, RIVFLOZA is only indicated for patients with PH1 [see INDICATIONS AND USAGE]. Unless otherwise noted, data are presented for the complete study population (PH1 and PH2).
Patients received monthly doses of RIVFLOZA (N=23) or placebo (N=12). The RIVFLOZA dose for patients at least 12 years of age weighing at least 50 kg was 160 mg, for patients at least 12 years of age weighing less than 50 kg was 128 mg, and for children 6 to 11 years of age was 3.3 mg/kg (to a maximum of 128 mg).
The median age was 20 years (range 9 - 46 years), 51% were female, 71% were White, 17% were Asian, 83% had PH1, and 17% had PH2. At baseline, mean 24-hour urinary oxalate excretion, normalized by 1.73 m² BSA in patients less than 18 years of age, was 1547 μmol/24-hour. Mean plasma oxalate was 8.2 μmol/L, 43% of patients had an eGFR ≥ 90 mL/min/1.73 m², 34% had an eGFR 60 to < 90 mL/min/1.73 m², 23% had an eGFR 30 to < 60 mL/min/1.73 m², and 60% were taking pyridoxine.
The primary efficacy endpoint was the area under the curve, from Days 90 to 180, of the percent change from baseline in 24-hour urinary oxalate excretion (AUC24-hour Uox). The least-squares (LS) mean AUC24-hour Uox was -3486 (95% CI: -5025, -1947) in the RIVFLOZA group compared to 1490 (95% CI: 781, 3761) in the placebo group, for a between group difference of 4976 (95% CI: 2803, 7149; p<0.0001).
The LS mean percent change from baseline in 24-hour urinary oxalate excretion (corrected for BSA in patients < 18 years of age) averaged over Days 90, 120, 150 and 180, was -37% (95% CI: -53%, -21%) in the RIVFLOZA group and 12% (95% CI: -12%, 36%) in the placebo group, for a between group difference of 49% (95% CI: 26%, 72%) [Figure 1]. Among patients with PH1, the between group difference was 56% (95% CI: 33%, 80%).
Figure 1: Mean (95% CI) Percent Change from Baseline in 24-hour Urinary Oxalate in RIVFLOZA and Placebo-Treated Patients in PHYOX2
 |
After 6 months of treatment in PHYOX2, patients could enroll in an ongoing single-arm extension study, PHYOX3 (NCT04042402), in which all patients were treated with RIVFLOZA. The reduction in urinary oxalate was maintained in the 13 patients with PH1 who received an additional 6 months of treatment in PHYOX3.
PHYOX8
PHYOX8 (NCT05001269) was a single-arm open-label multicenter study that included patients 2 years of age to less than 12 years of age with PH1 and an eGFR >30 mL/min/1.73 m².
The median age of patients at first dose was 5 years (range 2 to 10 years), 33% were female, and 80% were White. A total of 15 patients with PH1 completed treatment; 8 patients were 2 to less than 6 years of age, 5 patients were 6 to less than 9 years of age and 2 patients were 9 to 11 years of age. The mean spot urinary oxalate:creatinine ratio at baseline was 0.36 mmol/mmol.
The primary endpoint was the percent change from baseline in spot urinary oxalate:creatinine ratio at Month 6. Patients treated with RIVFLOZA had a 64% (95% CI: 44, 84) reduction in spot urinary oxalate:creatinine ratio from baseline at Month 6 (Figure 2). The corresponding absolute reduction in spot urinary oxalate:creatinine ratio at Month 6 was 0.25 mmol/mmol (95% CI: 0.21, 0.29).
Figure 2: PHYOX8: Mean (95% CI) Percent Change in Spot Urinary Oxalate: Creatinine Ratio from Baseline by Month
 |
After 6 months of treatment in PHYOX8, patients could enroll in an ongoing single arm extension study, PHYOX3. The reduction in urinary oxalate:creatinine ratio was maintained in the 8 patients who received an additional 6 months of treatment in PHYOX3.
RIVFLOZA®
(Riv-flo-za)
(nedosiran) injection, for subcutaneous use
What is RIVFLOZA?
RIVFLOZA is a prescription medicine used to lower urinary oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function.
It is not known if RIVFLOZA is safe and effective in children younger than 2 years of age.
Before using RIVFLOZA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How should I use RIVFLOZA?
What are the possible side effects of RIVFLOZA?
The most common side effects of RIVFLOZA include injection site reactions, such as reddening, pain, bruising, rash, or dimple at the site of injection.
These are not all the possible side effects of RIVFLOZA.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
You may also report side effects to Novo Nordisk at 1-844-906-5099.
How should I store RIVFLOZA?
Keep RIVFLOZA and all medicines out of the reach of children.
General information about the safe and effective use of RIVFLOZA.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use RIVFLOZA for a condition for which it was not prescribed. Do not give RIVFLOZA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about RIVFLOZA that is written for health professionals.
What are the ingredients in RIVFLOZA?
Active ingredient: nedosiran
Inactive ingredients: water for injection and sodium hydroxide and/or hydrochloric acid.
For more information contact: Dicerna Pharmaceuticals, Inc., A Novo Nordisk company
INSTRUCTIONS FOR USE
RIVFLOZA®
(Riv-flo-za)
(nedosiran) injection, for subcutaneous use
Single-dose vial
This Instructions for Use contains information on how to inject RIVFLOZA using the single-dose vial in:
Read the Instructions for Use before using RIVFLOZA vial and each time you get a refill. There may be new information. Ask your or your child's healthcare provider if you have any questions.
 |
Important information you need to know before injecting RIVFLOZA.
Supplies needed to give the injection
If the amount of RIVFLOZA needed for your or your child's prescribed dose is 0.5 mL or less, you will need the following supplies:
 |
 |
If the amount of RIVFLOZA needed for your or your child's prescribed dose is 0.6 mL or more, you will need the following supplies:
The following supplies are not included in the carton:
 |
How should I store RIVFLOZA vials?
Keep RIVFLOZA vials and all medicines out of the reach of children.
A. Preparing for the injection
Step 1. Gather the supplies and place the supplies on a clean, flat surface in a well-lit area.
 |
Step 2. Remove the RIVFLOZA vial carton(s) from the refrigerator.
 |
Caution:
Step 3. Wash your hands with soap and water.
Step 4. Open the carton(s) and remove the RIVFLOZA vial(s).
 |
Step 5. Inspect the RIVFLOZA vial(s).
 |
Step 6. Choose the injection site(s).
 |
Caution:
Step 7. Clean the injection site(s).
 |
Step 8. Prepare the vial(s).
 |
Caution
 |
B. Giving the injection
Step 9. Remove the syringe with attached needle from the packaging and remove the needle cap. Throw the needle cap away in the sharps disposal container.
 |
Caution:
Step 10. Withdraw RIVFLOZA into the syringe.
If the dose amount is 0.5 mL or less:
 |
If the dose amount is 0.6 mL or more:
 |
Step 11. Remove any large air bubbles from the syringe.
 |
Caution:
Step 12. Turn the vial and syringe back upright and remove the needle from the vial.
 |
Step 13. Pinch the skin and fully insert the needle.
 |
Step 14. Slowly inject all the medicine.
 |
Step 15. Remove the needle from the injection site.
Caution:
Throw away (dispose of) the used vial(s) in household trash.
If there is bleeding, lightly press a cotton ball or gauze over the injection site.
 |
C. After the injection
Step 16. Throw away (dispose of) the used syringe(s).
 |
Flip Page for More Information 
Frequently asked questions
What if a dose is missed?
If you have any questions about a missed dose, call your healthcare provider or pharmacist.
What if I damage or break the RIVFLOZA vial?
Do I inject the full volume of the vial?
What if I need 2 vials for injection?
“Pull Out” panel (on front of IFU)
INSTRUCTIONS FOR USE
Read Entire Instructions Before Use
Follow Instructions Carefully
Contact Novo Nordisk for any Questions
RIVFLOZA®
(Riv-flo-za)
(nedosiran) injection, for subcutaneous use
Single-dose vial
 |
Address Panel
For more information go to https://www.rivfloza.com/ or call 1-844-906-5099.
Flip Page for Instructions for Use 
INSTRUCTIONS FOR USE
RIVFLOZA®
(Riv-flo-za) (nedosiran) injection, for subcutaneous use
Single-dose Pre-filled Syringe
This Instructions for Use contains information on how to inject RIVFLOZA.
Read the Instructions for Use before using RIVFLOZA Pre-filled Syringe and each time you get a refill. There may be new information. Ask your or your child's healthcare provider if you have any questions.
RIVFLOZA Pre-filled Syringe Parts
RIVFLOZA Pre-filled Syringe is available in 2 dose strengths. You should check the label on the carton that comes with the RIVFLOZA Pre-filled Syringe to make sure you have the right Pre-filled Syringe for the prescribed dose.
For adults and children 12 years of age and older weighing less than 110 pounds (50 kilograms)
and
For children 2 years of age to less than 12 years of age weighing between 86 pounds (39 kilograms) and less than 110 pounds (50 kilograms):
 |
RIVFLOZA®
(nedosiran) injection
For subcutaneous injection only
For adults and children 2 years of age and older weighing 110 pounds (50 kilograms) or more:
RIVFLOZA®
(nedosiran) injection
For subcutaneous injection only
 |
Important information you need to know before injecting RIVFLOZA.
Supplies needed to give the injection:
The following supplies are not included in the carton:
 |
How should I store RIVFLOZA Pre-filled Syringe?
Keep RIVFLOZA Pre-filled Syringe and all medicines out of the reach of children.
INSTRUCTIONS FOR USE
 |
A. Preparing for the injection
Step 1. Gather the supplies and place the supplies on a clean, flat surface in a welllit area.
 |
Step 2. Remove the RIVFLOZA Pre-filled Syringe carton from the refrigerator.
 |
Caution:
 |
Step 3. Wash your hands with soap and water.
Step 4. Open the carton and remove the RIVFLOZA Pre-filled Syringe.
 |
Step 5. Inspect the RIVFLOZA Pre-filled Syringe.
 |
You may see small air bubbles in the liquid. This is normal.
Step 6. Choose the injection site.
You may inject into skin of:
Caution:
 |
Step 7. Clean the injection site.
 |
B. Giving the injection
Step 8. Remove the needle cap and throw it away in the sharps disposal container.
Caution:
 |
Step 9. Pinch the skin and fully insert the needle.
 |
Step 10. Slowly inject all the medicine.
 |
Step 11. Remove the RIVFLOZA Pre-filled Syringe from the injection site.
Caution:
If there is bleeding, lightly press a cotton ball or gauze over the injection site.
 |
C. After the injection
Step 12. Throw away (dispose of) the used RIVFLOZA Pre-filled Syringe.
 |
Flip Page for more Information 
Frequently asked questions
What if a dose is missed?
If you have any questions about a missed dose, call your healthcare provider or pharmacist.
What if I damage or break the RIVFLOZA Pre-filled Syringe?
Do I inject the full volume of the Pre-filled Syringe?
“Pull Out” panel (on front of IFU)
INSTRUCTIONS FOR USE
Read Entire Instructions Before Use
Follow Instructions Carefully
Contact Novo Nordisk for any Questions
RIVFLOZA®
(Riv-flo-za)
(nedosiran) injection, for subcutaneous use
Single-dose Pre-filled Syringe
 |
Flip Page for Instructions for Use 
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
